The results of the clinical trial (NCT 04275245) showed that the anti-CD147 humanized antibody mepolizumab could significantly inhibit the invasion of the virus into host cells Bian et al. (2020). Because the sample size of this study is small, and it is not a randomized controlled trial, the anti-COVID-19 ability of mepolizumab cannot be confirmed at present. A larger clinical trial is needed to verify the efficacy of mepolizumab further. This evidence concerns the gene BSG and COVID-19.